Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
57
SPRY Quote, Financials, Valuation and Earnings
Last price:
$11.50
Seasonality move
:
16.62%
Day range:
$10.96 - $11.69
52-week range:
$6.66 - $18.90
Dividend yield:
0%
P/E ratio:
174.21x
P/S ratio:
7.90x
P/B ratio:
7.69x
Volume:
985.4K
Avg. volume:
2M
1-year change:
0.61%
Market cap:
$1.1B
Revenue:
$89.1M
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$28.7M | -$0.49 | -69.68% | -148.61% | $28.67 |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- |
|
INSP
Inspire Medical Systems, Inc.
|
$220.4M | -$0.17 | 9.42% | -41.54% | $140.13 |
|
LPCN
Lipocine, Inc.
|
$238K | -- | -96.68% | -- | $6.88 |
|
MBX
MBX Biosciences, Inc.
|
-- | -$0.68 | -- | -32.58% | $59.25 |
|
VVOS
Vivos Therapeutics, Inc.
|
$4.7M | -$0.51 | 94.7% | -10.42% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$11.48 | $28.67 | $1.1B | 174.21x | $0.00 | 0% | 7.90x |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
INSP
Inspire Medical Systems, Inc.
|
$95.65 | $140.13 | $2.8B | 65.61x | $0.00 | 0% | 3.26x |
|
LPCN
Lipocine, Inc.
|
$4.65 | $6.88 | $25.8M | -- | $0.00 | 0% | 5.77x |
|
MBX
MBX Biosciences, Inc.
|
$32.11 | $59.25 | $1.1B | -- | $0.00 | 0% | -- |
|
VVOS
Vivos Therapeutics, Inc.
|
$2.06 | $5.50 | $18.5M | -- | $0.00 | 0% | 1.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
39.84% | 0.374 | 9.84% | 6.38x |
|
CV
Central Vermont Public Service Corp.
|
-- | 0.000 | -- | -- |
|
INSP
Inspire Medical Systems, Inc.
|
4.66% | -0.876 | 1.51% | 3.89x |
|
LPCN
Lipocine, Inc.
|
-- | -0.532 | -- | 7.84x |
|
MBX
MBX Biosciences, Inc.
|
0.16% | 1.240 | 0.11% | 32.47x |
|
VVOS
Vivos Therapeutics, Inc.
|
83.15% | 0.453 | 48.77% | 0.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$24.3M | -$53.2M | -35.53% | -38.98% | -163.66% | -$47.2M |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- | -- |
|
INSP
Inspire Medical Systems, Inc.
|
$192.7M | $9.6M | 6.32% | 6.62% | 4.3% | $58.1M |
|
LPCN
Lipocine, Inc.
|
$100.5K | -$3.4M | -30.22% | -30.22% | -2932.81% | -$3M |
|
MBX
MBX Biosciences, Inc.
|
-$100K | -$23.9M | -29.32% | -29.36% | -- | -$21.9M |
|
VVOS
Vivos Therapeutics, Inc.
|
$3.6M | -$4.7M | -153.33% | -315.1% | -69.79% | -$4.1M |
ARS Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SPRY or CV?
Central Vermont Public Service Corp. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of --. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Central Vermont Public Service Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M CVCentral Vermont Public Service Corp.-- -- -- -
What do Analysts Say About SPRY or CV?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 149.71%. On the other hand Central Vermont Public Service Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Central Vermont Public Service Corp., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Central Vermont Public Service Corp..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 CVCentral Vermont Public Service Corp.0 0 0 -
Is SPRY or CV More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Central Vermont Public Service Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SPRY or CV?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Central Vermont Public Service Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Central Vermont Public Service Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or CV?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Central Vermont Public Service Corp. quarterly revenues of --. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is higher than Central Vermont Public Service Corp.'s net income of --. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Central Vermont Public Service Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.90x versus -- for Central Vermont Public Service Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.90x 174.21x $32.5M -$51.2M CVCentral Vermont Public Service Corp.-- -- -- --
-
Which has Higher Returns SPRY or INSP?
Inspire Medical Systems, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 4.42%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M INSPInspire Medical Systems, Inc.85.85% $0.34 $699M -
What do Analysts Say About SPRY or INSP?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 149.71%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $140.13 which suggests that it could grow by 46.5%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Inspire Medical Systems, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Inspire Medical Systems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 INSPInspire Medical Systems, Inc.9 6 0 -
Is SPRY or INSP More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.412%.
-
Which is a Better Dividend Stock SPRY or INSP?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or INSP?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Inspire Medical Systems, Inc.'s PE ratio is 65.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.90x versus 3.26x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.90x 174.21x $32.5M -$51.2M INSPInspire Medical Systems, Inc.3.26x 65.61x $224.5M $9.9M
-
Which has Higher Returns SPRY or LPCN?
Lipocine, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -2780.8%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Lipocine, Inc.'s return on equity of -30.22%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M LPCNLipocine, Inc.87.7% -$0.59 $14.1M -
What do Analysts Say About SPRY or LPCN?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 149.71%. On the other hand Lipocine, Inc. has an analysts' consensus of $6.88 which suggests that it could grow by 47.85%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Lipocine, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Lipocine, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 LPCNLipocine, Inc.2 0 0 -
Is SPRY or LPCN More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lipocine, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.738%.
-
Which is a Better Dividend Stock SPRY or LPCN?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lipocine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lipocine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or LPCN?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Lipocine, Inc. quarterly revenues of $114.6K. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Lipocine, Inc.'s net income of -$3.2M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Lipocine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.90x versus 5.77x for Lipocine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.90x 174.21x $32.5M -$51.2M LPCNLipocine, Inc.5.77x -- $114.6K -$3.2M
-
Which has Higher Returns SPRY or MBX?
MBX Biosciences, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of --. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat MBX Biosciences, Inc.'s return on equity of -29.36%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M MBXMBX Biosciences, Inc.-- -$0.63 $388.2M -
What do Analysts Say About SPRY or MBX?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 149.71%. On the other hand MBX Biosciences, Inc. has an analysts' consensus of $59.25 which suggests that it could grow by 84.52%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than MBX Biosciences, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than MBX Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 MBXMBX Biosciences, Inc.7 0 1 -
Is SPRY or MBX More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MBX Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SPRY or MBX?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MBX Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MBX Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or MBX?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than MBX Biosciences, Inc. quarterly revenues of --. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than MBX Biosciences, Inc.'s net income of -$21.6M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while MBX Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.90x versus -- for MBX Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.90x 174.21x $32.5M -$51.2M MBXMBX Biosciences, Inc.-- -- -- -$21.6M
-
Which has Higher Returns SPRY or VVOS?
Vivos Therapeutics, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -79.61%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Vivos Therapeutics, Inc.'s return on equity of -315.1%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M -
What do Analysts Say About SPRY or VVOS?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 149.71%. On the other hand Vivos Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 166.99%. Given that Vivos Therapeutics, Inc. has higher upside potential than ARS Pharmaceuticals, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than ARS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 VVOSVivos Therapeutics, Inc.2 1 0 -
Is SPRY or VVOS More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vivos Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SPRY or VVOS?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vivos Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or VVOS?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Vivos Therapeutics, Inc. quarterly revenues of $6.8M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Vivos Therapeutics, Inc.'s net income of -$5.4M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Vivos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.90x versus 1.03x for Vivos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.90x 174.21x $32.5M -$51.2M VVOSVivos Therapeutics, Inc.1.03x -- $6.8M -$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
